Trisalus Life Sciences (TLSI) Registration Filing summary

Company overview and business model

• Focuses on oncology medical technology, integrating innovative delivery systems with immunotherapeutics for solid tumor treatment.

• Developed PEDD infusion systems and TriNav devices, with recent product launches expanding addressable markets.

• Conducts clinical trials for nelitolimod, a TLR9 agonist, and seeks pharmaceutical partners for further development.

• Holds permanent CMS reimbursement codes for TriNav products, supporting hospital and outpatient adoption.

• Registry studies and new indications aim to expand market opportunities, including thyroid disease procedures.

Financial performance and metrics

• Approaching revenue levels sufficient to sustain operations, with high growth and high margin profile.

• As of November 10, 2025, 49,964,311 shares of common stock were issued and outstanding.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including debt repayment, capital expenditures, product pipeline development, and strategic growth.

• Management has significant discretion over capital allocation.